HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Health, Beauty And Wellness News: FTC, FDA Enforcement, Noosh In Vitamin Shoppe, GNC Tests Store Features

This article was originally published in The Rose Sheet

Executive Summary

Dr. Schulze's warned on cancer claims; Nutrition 21 ingredients in BPI Sports, Olympus Labs supplements; GNC tests 'experiential' store features, helps promote ZanthSyn; Noosh Almond Protein in Vitamin Shoppe; and FTC says no more, Nobetes.

You may also be interested in...



FTC's Claimed Authority To Chase Permanent Injunctions, Monetary Relief May Lack Substantiation

The Federal Trade Commission has long held that Section 13(b) of the FTC Act authorizes the agency to seek permanent injunctions against, and monetary relief from, alleged violators of consumer protection provisions. But that understanding is being put to the test, and cracks are beginning to show, attorneys say.

'Free Trial' Plus False Claims Equals More FTC Enforcement In Supplement Market

FTC on consecutive days announced court order closing a California business allegedly charging consumers for products and enrolling them in negative-option continuity plans without their consent after they responded to bogus free trial online offers, and started mailing 16,596 checks totaling more than $750,000 to consumers who bought deceptively marketed supplements from a Maine firm that also lured customers with a free trial pitch.

Lucky STAR: FDA’s eSTAR Pilot Aims To Make 510(k) Process Smoother With Submission Template For Device Makers

Nine lucky manufacturers will soon have the chance to enroll in a voluntary eSTAR pilot program that the US agency says will make the premarket review process more efficient and consistent. The design and structure of an electronic Submission Template And Resource – or eSTAR – template is similar to templates used by FDA reviewers. An eSTAR won’t change the agency’s statutory or data requirements for sponsors to show substantial equivalence to predicate devices.

Topics

Related Companies

UsernamePublicRestriction

Register

RS122559

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel